Abstract. We have previously identified numerous tumor-rejection antigens and their epitope peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes (CTLs) in patients with various types of cancer. In the present study, we attempted to determine which antigens and their peptides are useful in specific immunotherapy for bladder carcinoma (BC) patients, especially those with human leukocyte antigen (HLA)-A24+ alleles. The mRNA expression of a panel of cancer-associated antigens was examined regarding four BC cell lines. As a result, three candidate antigens, including SART3, multidrug resistance-associated protein 3 (MRP3), and polycomb group protein enhancer of zeste homolog 2 (EZH2), were expressed in three of the four BC cell lines. Thereafter, antigen-derived peptides which we reported to induce cancer-reactive CTLs from HLA-A24+ patients with various types of cancer were examined for their potential to induce CTLs from peripheral-blood mononuclear cells of HLA-A24+ BC patients. Among these antigen-derived six peptides, SART3109-118, MRP31293-1301, and EZH2 735-742 peptides efficiently induced peptide-specific and BC cell-reactive CTLs from HLA-A24+ BC patients. The cytotoxicity against BC cells was dependent on peptide-specific CD8+ T cells. IgG reactive to the SART3109-118 peptide was frequently detected in the plasma of BC patients. This information could facilitate the development of effective peptide-based immunotherapy for HLA-A24+ BC patients.

Introduction

Approximately 75% of bladder carcinoma (BC) are of a superficial type and can be surgically removed. However, two-thirds of patients will develop tumor recurrence within 5 years (1). After the successful treatment of superficial bladder cancer with Bacillus Calmette-Guerin (BCG) was established in 1976, BCG therapy has been considered to be the most successful protocol for BC (2). On the other hand, cytokines, including interferons (IFNs), interleukin (IL)-2, and IL-12, were demonstrated as new effective immunotherapeutic agents for superficial BC in several clinical trials (3). In contrast to non-specific immunotherapy, recent advances in tumor-rejection antigens (4), and such antigen-derived peptides, recognized by cancer-reactive cytotoxic T lymphocytes (CTLs), have been applied in clinical trials of anticancer vaccine (5-8). However, information regarding vaccine candidates applicable to specific immunotherapy to BC is very limited.

We identified a panel of tumor antigens and their epitope peptides that are currently known to be recognized by cancer-reactive CTLs. One representative is SART3, and SART3-derived peptides possess the potential to induce human leukocyte antigen (HLA) class I-restricted CTLs in patients with several types of epithelial cancer (9-12). We have also reported that antigenic peptides derived from multidrug resistance-associated protein 3 (MRP3) and polycomb group protein enhancer of zeste homolog 2 (EZH2) can induce HLA class I-restricted CTLs from HLA-A24+ patients with various types of cancer (13,14). In the present study, we attempted to determine which antigens and their peptides are useful in specific immunotherapy for HLA-A24+ BC patients among a panel of tumor antigens and their peptides identified thus far.

Materials and methods

Patients. The study protocol (Protocol # 2484) was approved by the Institutional Ethics Review Board of Kurume University, and informed written consent was obtained from all the subjects from whom peripheral blood mononuclear cells (PBMCs) were obtained in this study. PBMCs
were prepared by Ficoll-Conray density gradient centrifugation and cryopreserved until they were used for the experiments. The expression of HLA-A24 molecule on PBMCs of cancer patients was determined by flow cytometry as described previously (15).

Cell lines. The bladder cell carcinoma cell lines, HT1376, EJ-1, UM-UC-3, and Tcc-SUP, were incubated in RPMI-1640 supplemented 10% fetal bovine serum (FBS). C1R-A24 is an HLA-A*2402-expressing C1R cell line (Dr M. Takiguchi, Kumamoto University, Japan). The HLA-A*2402-transfected cell line, HT1376-A24, was established as described previously (16).

Reverse transcriptase-polymerase chain reaction (RT-PCR). Total RNA was isolated from cancer cell lines using RNAzol™ B (Tel-Test Inc., Friendswood, TX). The cDNA was prepared using the SuperScript™ PRE amplification System for first-strand cDNA synthesis (Invitrogen, CA), and was amplified using the following primers: 5'-AAGTACGCCAACATGTGGC-3' (sense) and 5'-CTCTGCTCA TTGACAGAGC-3' (anti-sense) for SART3, 5'-TGCCGTCTTCAAGCTTATCC-3' (sense) and 5'-GGTGATACACAGA CAGGCTTCCC-3' (anti-sense) for MRP3, 5'-GGCATTTTCA CATGTGTCC-3' (sense) and 5'-TGCTTCAGGAGTTGTTTG-3' (anti-sense) for EZH2, 5'-ATAAGACACCAACCGCTCTCG-3' (sense) and 5'-GGTCCACCGCTGACA CGTGG-3' (anti-sense) for GAPDH. RT-PCR amplification of SART1, SART2, Her2/neu, CypB, ART1, ART4, CEA, and EGFR were done as described previously (17-20).

Induction of peptide-specific CTLs from PBMCs. Peptides with >90% purity were purchased from Biologica Co. (Nagoya, Japan). Influenza (Flu) virus, EB virus (EB), and HIV-derived peptides were used as controls binding to HLA-A24 alleles, as described previously (9). Assays for the detection of peptide-specific CTLs were performed according to a previously reported method with several modifications (21). Briefly, PBMCs were incubated with 10 μg/ml of each peptide in quadruplicate in a 96-well microplate (Nunc, Roskilde, Denmark). The culture medium consisted of 45% RPMI-1640, 45% AIM-V medium (Life Technologies, Gaithersburg, MD), 10% FBS, 100 units/ml IL-2, and 0.1 mM MEM non-essential amino acid solution (Life Technologies). On the 15th day of culture, cells were separated into 4 wells, and then cultured with the corresponding peptide-pulsed C1R-A24 cells. The HIV peptide was used a negative control. After an 18-h incubation, the IFN-γ production was determined by ELISA.

Cytotoxicity assay. Peptide-stimulated PBMCs were tested for their cytotoxicity against BC cell lines, HT1376 (HLA-A24 negative) and HT1376-A24 (HLA-A24 positive), by a standard 6-h 51Cr-release assay. Phytohemagglutinin (PHA)-activated T cells from HLA-A24 positive healthy donors were used as a negative control. After CD8+ T cells were positively isolated using a CD8-positive isolation kit (Dynal, Oslo, Norway), two-thousand 51Cr-labeled cells per well were cultured with effector cells in 96-round-well plates. The specific 51Cr-release was calculated, as described previously (22). The specificity of peptide-stimulated PBMCs was confirmed by a cold inhibition assay. Twenty-thousand unlabeled C1R-A24 cells, which were pre-pulsed with either the HIV peptide or a corresponding peptide, were used as cold target cells.

Detection of peptide-specific immunoglobulin G. Peptide-specific immunoglobulin G (IgG) levels in plasma were measured by ELISA as previously reported (22).

Results

mRNA expression of three cancer-associated antigens in BC cell lines. To date, we have identified a panel of cancer-associated antigen and their epitope peptides. These antigens include SART1, SART2, SART3, MRP3, EZH2, ART1, and EGFR. These results are shown in Table I. A panel of cancer-associated antigens can be used in bladder cancer immunotherapy.

Table I. Results of RT-PCR analysis of cancer-associated antigens expressed in BC cell lines.

<table>
<thead>
<tr>
<th></th>
<th>EJ-1</th>
<th>UM-UC-3</th>
<th>HT1376</th>
<th>Tcc-SUP</th>
<th>PBMC</th>
</tr>
</thead>
<tbody>
<tr>
<td>SART1</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>SART2</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>SART3</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>±</td>
<td>-</td>
</tr>
<tr>
<td>MRP3</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>EZH2</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>±</td>
<td>-</td>
</tr>
<tr>
<td>Her2/neu</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>CypB</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>ART1</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>±</td>
</tr>
<tr>
<td>ART4</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>±</td>
<td>±</td>
</tr>
<tr>
<td>CEA</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>±</td>
<td>-</td>
</tr>
<tr>
<td>EGFR</td>
<td>±</td>
<td>±</td>
<td>+</td>
<td>+</td>
<td>-</td>
</tr>
</tbody>
</table>

Intensity of RT-PCR products was judged as follows: -, not detectable; ±, weakly detectable; +, strongly detectable. SART, squamous-cell carcinoma antigen recognized by T cell; CypB, cyclophilin B; ART, ADP-rebosyltransferase; CEA, carcinoembryonic antigen; EGFR, epidermal growth factor receptor; PBMC, peripheral blood mononuclear cell.

Figure 1. mRNA expression of cancer-associated antigens in BC cell lines. RT-PCR was performed using cDNA from four RCC cell lines, EJ-1, UM-UC-3, HT1376, and Tcc-SUP. GAPDH was used as an internal control.

KOMOHARA et al.: VACCINE CANDIDATES FOR BLADDER CARCINOMA
We first performed RT-PCR analysis on four BC cell lines, HT1376, EJ-1, UM-UC-3, and Tcc-SUP, and normal PBMCs. These cancer-associated antigens were expressed in most of the four BC cell lines, and results are summarized in Table I. Because mRNA expression of SART1, SART2, ART1, ART4, and CypB were detected in normal PBMCs, and because Her2/neu, CEA, and EGFR are well characterized antigens by other investigators (27-29), we focused on three antigens SART3, MRP3, and EZH2, in the following experiments. The results of RT-PCR on these three antigens are shown in Fig. 1.

Induction of peptide-specific CTLs from HLA-A24+ BC patients. We next attempted to determine whether or not these antigen-derived peptides could have the potential to generate peptide-specific CTLs from the PBMCs of HLA-A24+ BC patients. Because we have already identified their epitope peptides possessing the ability to induce cancer-reactive CTLs from HLA-A24+ patients with other types of cancer (12-14), we utilized the following six peptides: SART3109-118, MRP31293-1301, EZH2291-299, and EZH2735-742. The PBMCs from HLA-A24+ BC patients were stimulated in vitro with each of the peptides or control peptides, and were then examined for IFN-γ production in response to the corresponding peptide-pulsed C1R-A24 cells. The result was that these six peptides induced corresponding peptide-reactive CTLs in 4, 2, 1, 2, 2, and 4 of 8 BC patients (Fig. 2). Regarding each cancer-associated antigen, the SART3109-118, MRP31293-1301, and EZH2735-742 peptides appeared to be superior to another counterpart peptide. Flu and EBV peptides were used as positive controls. The induction rate of the SART3109-118 and EZH2291-299 peptides was comparable to that of the control peptides. In total, three peptide candidates, the SART3109-118, MRP31293-1301, and EZH2735-742, were further examined in the following experiments.

Cytotoxicity of peptide-stimulated PBMCs against BC cells. We next determined whether or not CTLs induced by in vitro stimulation with peptides could exhibit cytotoxicity against BC cells. The PBMCs from patients 5 and 8 were stimulated in vitro with each of the three peptides, SART3109-118, MRP31293-1301, and EZH2735-742, and their cytotoxicity against HLA-A24+ HT1376 cells, and its HLA-A24+ expressing transfectant cells, HT1376-A24, was measured. The PHA-stimulated T cell blasts from HLA-A24+ healthy donors were used as a control for HLA-A24+ and antigen-negative cells. As shown in Fig. 3A, the PBMCs from patient 5 that were stimulated in vitro with either the MRP31293-1301 or EZH2735-742 peptide exhibited a higher level of cytotoxicity against HT1376-A24 cells than against HT1376 cells and HLA-A24+ T cell blasts. The PBMCs from patient 8 that were stimulated in vitro with the SART3109-118 peptide also showed a higher level of cytotoxicity against HT1376-A24 cells than against HT1376 cells and HLA-A24+ T cell blasts. These results indicate that CTLs that were stimulated in vitro with each of the three peptides could exhibit cytotoxicity against BC cells in an HLA-A24-restricted manner.

Peptide-specific and CD8+ T cell-dependent cytotoxicity against BC cells. We further tried to identify cells responsible for the
cytotoxicity of peptide-stimulated CTLs. The cytotoxicity against HLA-A24+ and corresponding antigen-expressing HT1376-A24 cells was significantly suppressed by the addition of corresponding peptide-pulsed unlabeled C1R-A24 cells, but not by control HIV peptide-pulsed unlabeled C1R-A24 cells (Fig. 3B). These results indicate that the cytotoxicity of peptide-induced CTLs against HLA-A24+ BC cells is dependent on peptide-specific CD8+ T cells.

Detection of IgG reactive to SART3, MRP3, and EZH2-derived peptides. We have previously reported that IgGs reactive to CTL-directed peptides are detected in patients with epithelial cancers (13,14), and that increases in the level of peptide-specific IgG after peptide vaccination are positively correlated with the clinical response and survival of vaccinated patients (4,23). We therefore tested whether IgGs reactive to the SART3-, MRP3-, and EZH2-derived peptides could be detected in the plasma of cancer patients (n=15) and healthy donors (n=14). In BC patients, IgGs reacting to the SART3109-118 and SART3 315-323 peptides were detected in ten and six of 15 BC patients, respectively (Fig. 4). IgG reactive to either MRP3 503-511 or EZH2 735-743 peptide was not detected in any of these patients, and IgGs reactive to the MRP3 1293-1302 and EZH2 291-299 peptides were detected in only one and three patients (data not shown). No IgG was detected in any healthy donors (data not shown). These results indicate that the SART3 109-118 peptide is efficiently recognized by both the cellular and humoral immune systems.

Discussion

In our previous study, we identified SART3-, MRP3-, and EZH2-derived peptides that possess the potential to induce cancer-reactive CTLs from HLA-A24+ patients with various types of cancer other than BC (9-14). As for these cancer-associated antigens, SART3 is expressed in the nucleus of all the malignant tumor cell lines of various histological
types, whereas no analysis on BC has been done (15). In contrast, MRP3 and EZH2 were reported to be expressed in BC tissues (30-33). MRP3 is a widely-expressed cancer-associated antigen that we identified using tumor-infiltrating lymphocytes into lung adenocarcinoma (14). This antigen seems to be a unique target molecule for cancer vaccines because the expression of MRP3 is associated with multidrug resistance (34), which is an important problem in chemotherapy. On the other hand, EZH2 is a polycomb group protein homologue to the Drosophila enhancer of zeste (35). EZH2 is involved in gene silencing, and dysregulation of this gene-silencing machinery can lead to cancer (36).

In this study, we confirmed the expression of MRP3 and EZH2 in BC cell lines, and newly found that three of four bladder carcinoma cell lines were positive for SART3. Furthermore, we showed that these antigen-derived three peptides efficiently induced BC-reactive CTLs from the PBMCs of HLA-A2+ BC patients. A cold inhibition assay clearly revealed that the cytotoxicity toward HLA-A2+ BC cells was ascribed to peptide-specific CD8+ T cells. Both the preferential expression in BC cells and the potential of their peptide candidates to induce BC-reactive CTLs suggest that the identified three peptides would be appropriate vaccine candidates for use in specific immunotherapy for HLA-A2+ BC patients.

We determined whether IgG reactive to 6 peptide candidates could be detected in 15 BC patients. As a result, IgGs reactive to the SART3 109-118 peptide was detected more frequently compared to the other five peptides. Interestingly, IgGs reactive to the SART3 109-118 and SART3 151-158 peptides were detected more frequently in HLA-A24+ BC patients (Fig. 4, No. 1-8) than in HLA-A24- BC patients (Fig. 4, No. 9-15). In contrast, we previously observed that humoral responses to CTL-directed peptides were not restricted to HLA class I molecules (37,38). These observations seem to be discrepant. Although one explanation is that peptides used for assays were different, we have no clear explanation for this observation at present. We are trying to elucidate roles of peptide-specific IgG in anti-tumor immune responses in cancer patients.

Acknowledgements

This study was supported in part by Grants-in-Aid from the Ministry of Education, Science, Sports and Culture of Japan (KAKENHI; no. 16591628 to K.M, no. 16790933 to S.S, no. 18591449 to M.H.).

References


